29 Mar 2019 07:00
REDX PHARMA PLC
("Redx" or "the Company")
Redx Pharma to present two posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting
Posters show that RXC004 has the ability to directly target tumour growth and stimulate the host immune response against tumours
Alderley Park, 29 March 2019 - Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that the two abstracts submitted by the Company have been accepted for presentation as posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, taking place between 29 March and 3 April 2019.
Both posters relate to the Company's lead oncology candidate, RXC004, a selective, orally bioavailable porcupine (PORCN) inhibitor which targets the Wnt signalling pathway. The posters present preclinical data confirming the potential for RXC004 in modulating the immune system of the tumour microenvironment (poster #506) as well as preclinical data on the direct tumour-targeting effects of RXC004 in genetically-defined models of cancer (poster #3874).
Redx is evaluating RXC004 in an ongoing first-in-man clinical trial. The trial is a modular, multi-arm, multi-part, Phase 1/2a, adaptive design study whose primary objective is to evaluate the safety and tolerability of the drug in patients with advanced malignancies (ClinicalTrials.gov Identifier: NCT03447470).
Richard Armer, Chief Scientific Officer of Redx Pharma plc commented, "We are delighted to be presenting again at this high-profile cancer conference. These poster presentations demonstrate our continued understanding of how RXC004 is able to have both direct and immunomodulatory effects on tumours in various preclinical cancer models. This preclinical data will inform design of future clinical studies to investigate the full potential of this mechanism."
Details of the poster presentations are as follows:
1)
Abstract Title: | Wnt/β-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer |
Session Title: | Metabolic Mechanisms That Modulate the Immune Response to Cancer |
Date/Time: | March 31, 2019, 1:00 PM - 5:00 PM CST |
Location: | Poster Section 21 |
Poster Board Number: | 5 |
Poster Number: | 506 |
2)
Abstract Title: | Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer |
Session Title: | Novel Antitumor Agents 2 |
Date/Time: | April 2, 2019, 1:00 PM - 5:00 PM CST |
Location: | Poster Section 12 |
Poster Board Number: | 24 |
Poster Number: | 3874 |
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 920 |
Lisa Anson, Chief Executive Officer |
|
Andrew Saunders, Chief Medical Officer |
|
|
|
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
|
|
|
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin |
|
About Redx Pharma Plc
Redx is a UK-based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/
REDX.L (REDX)